Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215540 · ClinicalTrials.gov registry record · Phase 2
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
A Phase 2 study, sponsored by Windtree Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT00215540: Clinical Trial Phase 2 study, sponsored by Windtree Therapeutics.
NCT00215540 is a Phase 2 study that was terminated before completion, run by Windtree Therapeutics. The registered enrollment target is 136 participants, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00215540, a Phase 2 study, was terminated before completion, sponsored by Windtree Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required continued intubation and received surfactants for the prevention or treatment of respiratory distress syndrome (RDS).
Primary Outcome
Number of participants who died or developed BPD, defined as oxygen requirement at 36 Weeks post-menstrual age
Interventions
- DRUG Placebo
- DRUG Lucinactant 175 mg/kg
- DRUG Lucinactant 90 mg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2005-02 |
| Est. Completion | 2006-07 |
| Phase | Phase 2 |
Why NCT00215540 stopped before completion
NCT00215540 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00215540 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00215540 about?
NCT00215540 is a clinical study titled "SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.". SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required continued intubation and received surfactants for the prevention or treatment...
What is the current status of trial NCT00215540?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2005-02. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00215540?
The interventions under investigation include: Placebo (DRUG), Lucinactant 175 mg/kg (DRUG), Lucinactant 90 mg/kg (DRUG).
Who is sponsoring clinical trial NCT00215540?
This trial is sponsored by Windtree Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00215540's enrollment target sits among peer trials
136 527th of 2000 higher than 1,469 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia